Search clinical trials for: CTT1057

Total 23 results

Cancer Targeted Technology
University of California, San Francisco

Completed

A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057

Prostate Cancer

United States
Cancer Targeted Technology
University of California, San Francisco

Completed

CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Novartis Pharmaceuticals

Completed

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection (GuideView)

Prostatic Neoplasms | Prostate Cancer

Spain, Italy, France, Switzerland, United States
National Institute of Allergy and Infectious Diseases...

Terminated

Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

Idiopathic CD4+ T-Lymphocytopenia

United States
Cytheris SA

Terminated

Study on Interleukin-7 (CYT107) in HIV Patients (Inspire 2)

HIV

United States, Canada
Cancer Targeted Technology
National Cancer Institute (NCI); University of California, San Francisco

Completed

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
Revimmune
C.R.O. ReSolution Latin America S.A.

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) (ILIAD-7-BRA)

COVID-19 | Lymphocytopenia

Brazil
Revimmune
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Cancer Research... and other collaborators

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) (ILIAD-7-US-O)

COVID-19 | Lymphocytopenia

United States
Novartis Pharmaceuticals

Completed

Study of Diagnostic Performance of [18F]CTT1057 in BCR (GuidePath)

Recurrence | Prostatic Neoplasms | Prostate Cancer

Spain, France, Switzerland, United States
Revimmune
University Hospital, Limoges; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort (ILIAD-7-FR)

COVID-19 | Lymphocytopenia

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Revimmune

Withdrawn

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Umbilical Cord Blood Transplant
Cytheris, Inc.

Completed

Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

AML | MDS | CML

United States
Revimmune
Washington University School of Medicine

Terminated

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)

Mycobacterium Infections, Nontuberculous

United States
Revimmune
Washington University School of Medicine; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) (ILIAD-7-US-I)

COVID-19 | Lymphocytopenia

United States
Revimmune
Amarex Clinical Research

Terminated

InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort (ILIAD-7-UK)

COVID-19 | Lymphocytopenia

United Kingdom
Cytheris SA

Completed

Safety Study of IL-7 in HIV-infected Patients (Inspire)

HIV Infections | Lymphopenia

United States, France, Canada, Italy
Revimmune
Washington University School of Medicine; Vanderbilt University School of Medicine

Completed

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-B)

Severe Sepsis With Septic Shock

United States
Cytheris SA

Terminated

Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders (Inspire 3)

HIV

Switzerland, Italy, South Africa
Revimmune
Washington University School of Medicine; University Hospital, Limoges; George...

Terminated

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-C&D)

Sepsis, Severe

United States, France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Cancer Immunotherapy Trials Network

Completed

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone

United States
Cytheris SA

Unknown

Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients (CONVERT)

Chronic Hepatitis B

France, Italy
Newron Pharmaceuticals SPA

Completed

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist (MOTION)

Idiopathic Parkinson's Disease

United States, Spain, Brazil, Peru, Colombia, Germany, Argentina, India, Croatia, Czech Republic, Italy, South Africa, Finland, Portugal, Canada, Slovakia, Bulgaria, Chile, Mexico, Poland
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder... and other conditions

United States

Search clinical trials for: CTT1057

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations